Dermisonics Net Current Asset Value from 2010 to 2026
Dermisonics' Net Current Asset Value is steady with stable movements from year to year. Net Current Asset Value will most likely to flatten out to 0.00. The current Discontinued Operations is estimated to decrease to about (32.6 K). The current Selling General Administrative is estimated to decrease to about 3.8 M. View All Fundamentals
Check out the analysis of Dermisonics Correlation against competitors. For more detail on how to invest in Dermisonics Stock please use our How to Invest in Dermisonics guide.
Net Current Asset Value | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Dermisonics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermisonics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 3.8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.04. Dermisonics financial statements analysis is a perfect complement when working with Dermisonics Valuation or Volatility modules.
Dermisonics | Net Current Asset Value | Build AI portfolio with Dermisonics Stock |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Dermisonics Correlation against competitors. For more detail on how to invest in Dermisonics Stock please use our How to Invest in Dermisonics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is there potential for Medical Devices market expansion? Will Dermisonics introduce new products? Factors like these will boost the valuation of Dermisonics. Projected growth potential of Dermisonics fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dermisonics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Dermisonics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Dermisonics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Dermisonics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Dermisonics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermisonics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Dermisonics' market price signifies the transaction level at which participants voluntarily complete trades.